Medtronic PLC shares were down 1.3% premarket on Thursday after advisors to the U.S. Food and Drug Administration had a mixed reaction to the company’s...
Medtronic PLC shares MDT, -0.05% were down 1.3% premarket on Thursday after advisors to the U.S. Food and Drug Administration had a mixed reaction to the company’s investigational renal denervation system, used to treat high blood pressure. In a close vote, the advisory committee said the benefits of the system, Symplicity Spyral, did not outweigh the risks, although the panel voted favorably on the system’s safety and effectiveness. Advisory committee votes are not binding.
But “given the vote, we think that the FDA is unlikely to approve Symplicity Spyral,” Needham analysts wrote in a note Thursday. Other analysts saw a more positive outcome. Raymond James analysts said in a note late Wednesday that they still believe Medtronic will ultimately get FDA approval for the device, although the label may be narrower than anticipated.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
US FDA panel votes against use of Medtronic's blood pressure treatment device By ReutersUS FDA panel votes against use of Medtronic's blood pressure treatment device
Read more »
Medtronic raises profit forecast as surgeries return to pre-pandemic levels By ReutersMedtronic raises profit forecast as surgeries return to pre-pandemic levels
Read more »
The Lane School in Clarendon Hills awarded Model PLC honorThe Lane School in Clarnedon Hills is among 12 schools in Illinois that has earned District 181′s first Model PLC (Professional learning community ) at Work School honor.
Read more »
Atlassian Corp Plc Stock Price Today | NASDAQ TEAM Live TickerView today's Atlassian Corp Plc stock price and latest TEAM news and analysis. Create real-time notifications to follow any changes in the live stock price.
Read more »
Experts: FDA approval of postpartum depression pill a positive stepZurzuvae is accessible and can treat symptoms more quickly and effectively
Read more »